Vir Biotechnology (VIR) Net Cash Flow (2018 - 2026)

Vir Biotechnology's Net Cash Flow history runs 9 years deep, the most recent figure standing at $42.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 14.86% year-over-year to $42.0 million; the TTM figure through Mar 2026 stood at -$85.0 million (down 145.3% YoY), while the FY2025 annual figure was -$77.6 million, down 235.23% from the prior year.
• Net Cash Flow came in at $42.0 million for Q1 2026 at Vir Biotechnology, down from $61.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $690.9 million in Q2 2022 to a low of -$542.7 million in Q3 2022.
• A 5-year average of -$4.7 million and a median of -$52.8 million in 2024 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 452.44% in 2022 and fell as far as 1816.04% in 2022.
• Vir Biotechnology's Net Cash Flow stood at -$116.0 million in 2022, then tumbled by 81.95% to -$211.1 million in 2023, then surged by 125.76% to $54.4 million in 2024, then gained by 13.7% to $61.8 million in 2025, then sank by 32.1% to $42.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $42.0 million, $61.8 million, and -$127.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison